QWM
BMRN icon

Quaker Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quaker Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$707 – 973
2025
Q1 		$707 Buy
+10
New +$673 ﹤0.01% 554

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Quaker Wealth Management's BMRN Position: Q2 2026 in Review

Quaker Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q2 2026, selling an estimated $219 and leaving 4 shares worth $229. The position accounts for ﹤0.01% of the portfolio, ranked #868.

Quaker Wealth Management first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $452 in Q1 2026. 148 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Quaker Wealth Management held 4 shares of BioMarin Pharmaceuticals worth $229 as of Q2 2026.
  • Quaker Wealth Management sold 4 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $219.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Quaker Wealth Management's portfolio in Q2 2026, its #868 holding.
  • Quaker Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Quaker Wealth Management's BioMarin Pharmaceuticals position peaked at $452 in Q1 2026.
  • 148 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Quaker Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.